Hemodynamic Peptide Modulation for Fluid Overload in Critical Care
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fluid overload and acute kidney injury in critically ill patients are ineffective, leading to prolonged hospital stays, increased mortality, and high healthcare costs, with diuretics offering no conclusive evidence of altering major outcomes.
Innovation Solution
Administration of a hemodynamic peptide comprising at least 50% autophagy inhibiting amino acids such as alanine, glutamine, glycine, valine, leucine, and proline, which improves hemodynamic stability and reduces adverse vascular permeability and fluid retention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous fluid therapy is administered to treat fluid overload and improve hemodynamic stability, then hemodynamic stability is improved, but fluid retention and adverse vascular permeability worsen
Solution Approach 1:
The patent uses amino acids as intermediary substances that mediate between fluid therapy and its adverse effects. The amino acid solution acts as a mediator that provides hemodynamic stability while preventing fluid retention and vascular permeability issues, resolving the contradiction between improving hemodynamics and avoiding fluid overload
Solution Approach 2:
The patent changes the chemical composition parameter of the infusion solution from traditional crystalloids or colloids to amino acid-based solutions. This parameter change fundamentally alters how the fluid interacts with vascular systems, providing hemodynamic support without causing fluid retention or increased vascular permeability
2Quantity of substance
If conventional treatments (diuretics) are used to manage fluid overload, then fluid removal is attempted, but mortality and length of stay are not significantly reduced
Solution Approach 1:
The patent applies preliminary action by preventing fluid overload from occurring in the first place through amino acid infusion. Rather than attempting to remove fluid after overload occurs (reactive approach), the amino acid therapy proactively maintains proper fluid balance and prevents the development of fluid retention, thereby avoiding prolonged hospital stays
Solution Approach 2:
The patent converts the potential harm of fluid therapy into benefit by using amino acids that provide hemodynamic support without causing fluid retention. The substance that could potentially contribute to fluid overload is transformed into a protective agent that prevents fluid retention while maintaining circulation
3Reliability
If fluid therapy is increased to treat hemodynamic instability, then hemodynamic parameters improve, but adverse vascular permeability and organ function worsen
Solution Approach 1:
Amino acids serve as an intermediary substance that improves hemodynamic parameters without directly causing vascular permeability issues. They mediate the relationship between fluid therapy and vascular integrity, providing circulatory support while protecting against capillary leakage and tissue edema
Data Source
AI summary
This disclosure provides method of treatment comprising administering an AQGV peptide, or a functional analog thereof, to a human subject, the human subject optionally having impaired kidney function, wherein the treatment of administering an AQGV peptide comprises maintaining or improving hemodynamic stability in the human subject, such as a human subject suffering or considered suffering from Clarkson's disease (CLS).